$Palatin Technologies (PTN.US)$Reuters· just FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for Pl9643 in Dry Eye Disease (Ded)
$Palatin Technologies (PTN.US)$ First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity Palatin Technologies (NYSE American: PTN) has initiated patient dosing in a Phase 2 clinical study of bremelanotide co-administered with tirzepatide for obesity treatment. The study, BMT-801, aims to enroll up to 60 patients across four U.S. sites, with full enrollment expected in Q3 2024 and topline results in Q1 2025....
Palatin Technologies股票討論
帕拉丁完成了與提澤帕肽（GLP-1/GIP）聯合施用Bremelanotide（MC4R Agonist）治療肥胖的第2期臨床研究招募。
• 預計於2025年第一季度公佈頂線結果
• 該研究正在評估bremelanotide和tirzepatide聯合使用對減輕體重的影響
• 數據將會為公司的肥胖計劃提供支持和資訊，使用新穎、長效和高度選擇性的MC4R肽和小分子化合物...
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
• Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)
◦ Patient Dosing Commenced 3Q Calendar Year 2024
◦ Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024
◦ Topline Results Expected 1Q Calendar Year 2025
• Dry Eye...
3分鐘前，美東時間上午7點30分
透過PR資訊新聞
乾眼症(DED)：PL9643
◦ MELODY-2和MELODY-3第3期臨床試驗
▪ FDA確認方案和終點
▪ 預計在2024年第4季開始招生
▪ 預計在2025年第4季公佈頂線結果
◦ 潛在的合作/融資討論正在進行中
• 肥胖症：第2期臨床研究 ...
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for Pl9643 in Dry Eye Disease (Ded)
FDA證實資訊Palatin在乾眼症（DED）中PL9643的剩餘第3期關鍵性臨床試驗是可接受的
Palatin Technologies（紐交所美國：PTN）已收到FDA對其乾眼症（DED）中PL9643剩餘第3期關鍵性臨床試驗的方案和終點的確認。 MELODY-2和MELODY-3試驗預計將於2024年第4季開始招募患者，預計到2025年底將發佈頂線結果。如果成功，預計將在2026年上半年提交新藥申請...
帕拉丁（Palatin）的Bremelanotide聯合Tirzepatide（GLP-1）用於肥胖治療的2期臨床研究中，首名患者已接受用藥。
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies (NYSE American: PTN) has initiated patient dosing in a Phase 2 clinical study of bremelanotide co-administered with tirzepatide for obesity treatment.
The study, BMT-801, aims to enroll up to 60 patients across four U.S. sites, with full enrollment expected in Q3 2024 and topline results in Q1 2025....
暫無評論